G Bradley Cole Sells 7,403 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director G Bradley Cole sold 7,403 shares of Castle Biosciences stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $28.47, for a total value of $210,763.41. Following the completion of the sale, the director owned 19,309 shares of the company’s stock, valued at $549,727.23. The trade was a 27.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Castle Biosciences Price Performance

CSTL opened at $26.60 on Wednesday. The company’s 50-day simple moving average is $35.42 and its two-hundred day simple moving average is $31.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. The stock has a market capitalization of $790.82 million, a P/E ratio of -31.29 and a beta of 1.09. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. The firm had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. As a group, analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: New clinical data bolstering DecisionDx‑Melanoma: a large prospective multicenter study presented at SSO 2026 reported just 2.6% nodal positivity for patients the test predicts are <5% risk, supporting guideline guidance to avoid sentinel‑node biopsy in low‑risk patients — this validates the test’s clinical utility and could help adoption. DecisionDx Melanoma study
• Positive Sentiment: Recent quarterly results and analyst activity are supportive: the Feb. 26 quarter beat EPS expectations (‑$0.08 vs. est. ‑$0.23) and revenue roughly matched estimates; several firms raised price targets and maintain buy/outperform views — a fundamental backdrop that can undercut deeper selloffs. MarketBeat earnings & analyst note
• Neutral Sentiment: Institutional ownership is high (reported ~92.6%) with some funds adding shares in Q4, which can reduce float and increase stability, though it also concentrates risk. Institutional holdings detail
• Neutral Sentiment: Short‑interest reports in early March show anomalous “0 shares” / NaN values and a 0.0 days‑to‑cover metric — data likely erroneous or delayed, so current short‑interest impact is unclear. (No actionable short‑squeeze signal from these reports.)
• Negative Sentiment: Insider selling: CFO Frank Stokes sold 6,001 shares (avg ~$27.98) on March 5 (and sold 7,000 shares on March 3); Director G. Bradley Cole sold 7,403 shares (~$28.47). Multiple recent insider disposals can pressure sentiment and be interpreted as insiders taking profits. Insider trades report

Institutional Investors Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of CSTL. RTW Investments LP bought a new position in Castle Biosciences in the 4th quarter worth $82,283,000. AIGH Capital Management LLC bought a new stake in Castle Biosciences during the third quarter valued at about $16,105,000. Summit Partners Public Asset Management LLC grew its holdings in Castle Biosciences by 164.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after purchasing an additional 658,725 shares during the period. Braidwell LP increased its position in Castle Biosciences by 125.3% in the second quarter. Braidwell LP now owns 822,735 shares of the company’s stock worth $16,800,000 after buying an additional 457,488 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new position in shares of Castle Biosciences in the fourth quarter worth about $11,864,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CSTL has been the subject of a number of research reports. Guggenheim boosted their target price on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Robert W. Baird lifted their price objective on Castle Biosciences from $41.00 to $44.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Canaccord Genuity Group upped their price objective on Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Morgan Stanley raised Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Finally, Lake Street Capital raised their target price on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and an average target price of $47.57.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.